RiskOn International, Inc.: Nasdaq/NYSE listing notice — RiskOn International receives Nasdaq deficiency notice for bid price below $1.00

RiskOn International, Inc.

Received Nasdaq deficiency letter on Nov 2, 2023 for non-compliance with minimum bid price rule; stock closed below $1.00 for 31 consecutive days.
Has 180 calendar days, until April 30, 2024, to regain compliance by closing at $1.00 or more for 10 consecutive business days.
If not cured, may seek additional 180-day period if eligible; otherwise delisting possible with appeal rights.
Common stock continues trading on Nasdaq Capital Market under symbol ROI; no immediate effect on listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

RiskOn International, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 2, 2023, RiskOn International, Inc. (the “Company”) received a notice in the form of a letter (“Deficiency Letter”) from the Listing Qualifications Staff of the Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 31 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 30, 2024, to regain compliance. The Deficiency Letter states that to regain compliance, the bid price f

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001214659-23-014547

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.